REMINDER: Our user survey closes TODAY, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

15 Oct 2021 11:17

RNS Number : 2522P
Diurnal Group PLC
15 October 2021
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BDB6Q760

Issuer Name

DIURNAL GROUP PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Polar Capital LLP

City of registered office (if applicable)

 

Country of registered office (if applicable)

GB

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

13-Oct-2021

6. Date on which Issuer notified

14-Oct-2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

10.090000

0.000000

10.090000

17068585

Position of previous notification (if applicable)

9.020000

0.000000

9.020000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BDB6Q760

17068585

0

10.090000

0.000000

Sub Total 8.A

17068585

10.090000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Polar Capital Holdings PLC

0.000000

0.000000

0.000000%

Polar Capital Partners Limited

0.000000

0.000000

0.000000%

Polar Capital US Holdings Limited

0.000000

0.000000

0.000000%

Polar Capital (America) Corporation

0.000000

0.000000

0.000000%

Polar Capital Holdings LLC

0.000000

0.000000

0.000000%

Phaeacian Partners Holdings LP

0.000000

0.000000

0.000000%

Polar Capital LLP

10.090000

0.000000

10.090000%

Phaeacian Partners LLC

0.000000

0.000000

0.000000%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

14-Oct-2021

13. Place Of Completion

London, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLGPGAGUUPGGUA
Date   Source Headline
17th Sep 202012:40 pmEQSHardman & Co Research: Diurnal Group (DNL): Closely watching the regulators
15th Sep 20207:00 amRNSResults for the year ended 30 June 2020
11th Sep 20207:00 amRNSShares and AJ Bell Investor Evening Webinar
3rd Sep 20205:33 pmRNSHoldings in Company
3rd Sep 20207:00 amRNSTwo further marketing and distribution agreements
27th Aug 20207:00 amRNSRichard Ross receives honour by Endocrine Society
20th Aug 20207:15 amEQSHardman & Co Research: Diurnal Group (DNL): Q&A with Dr Martin Hall
19th Aug 202010:00 amRNSNotice of Full Year Results
13th Aug 20202:06 pmRNSSecond Price Monitoring Extn
13th Aug 20202:00 pmRNSPrice Monitoring Extension
13th Aug 20207:15 amEQSHardman & Co Research: Diurnal Group (DNL): Flow of regulatory approvals
10th Aug 20209:14 amRNSHolding(s) in Company
10th Aug 20207:00 amRNSAlkindi approved in Australia
5th Aug 20207:00 amRNSAlkindi approved in Israel
30th Jul 20204:41 pmRNSSecond Price Monitoring Extn
30th Jul 20204:35 pmRNSPrice Monitoring Extension
30th Jul 20202:06 pmRNSSecond Price Monitoring Extn
30th Jul 20202:00 pmRNSPrice Monitoring Extension
30th Jul 202011:05 amRNSSecond Price Monitoring Extn
30th Jul 202011:00 amRNSPrice Monitoring Extension
30th Jul 20207:01 amRNSBusiness and trading update
30th Jul 20207:00 amRNSPositive DITEST Regulatory Meeting with US FDA
29th Jul 20204:41 pmRNSSecond Price Monitoring Extn
29th Jul 20204:36 pmRNSPrice Monitoring Extension
15th Jul 20201:04 pmRNSDirector Dealings
13th Jul 20201:29 pmRNSDirector Dealings and Issue of Equity
13th Jul 20201:28 pmRNSGrant of Deferred Share Awards
26th Jun 20202:29 pmRNSDirector Dealings
9th Jun 20207:00 amRNSChronocort Phase 3 data at ENDO Online 2020
29th May 20207:00 amRNSChange of Adviser
30th Apr 20209:05 amRNSSecond Price Monitoring Extn
30th Apr 20209:00 amRNSPrice Monitoring Extension
21st Apr 202010:05 amRNSDirector Dealings and Issue of Equity
16th Apr 20202:23 pmRNSDirector Dealings
15th Apr 20204:41 pmRNSSecond Price Monitoring Extn
15th Apr 20204:36 pmRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSOperational Update
6th Apr 20209:21 amRNSDirector Dealings
1st Apr 20207:00 amRNSChronocort MAA Passes Validation Stage with EMA
30th Mar 20206:18 pmRNSHolding(s) in Company
30th Mar 20203:05 pmEQSHardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet further
27th Mar 20205:26 pmRNSHolding(s) in Company
27th Mar 20209:17 amRNSDirector Dealings
27th Mar 20207:00 amRNSUS Licencing Agreement with Eton Pharmaceuticals
26th Mar 20202:05 pmRNSSecond Price Monitoring Extn
26th Mar 20202:00 pmRNSPrice Monitoring Extension
25th Mar 20202:47 pmRNSResult of General Meeting and Issue of Equity
20th Mar 20204:48 pmRNSSecond Price Monitoring Extn
20th Mar 20204:39 pmRNSPrice Monitoring Extension
6th Mar 20204:55 pmRNSResult of Placing and Notice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.